Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | RAD52 | P43351 | 2/20 | 0.40 |
| ▸ | NQO1 | P15559 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31694921 | 1.00 | ELANE (0.49) | ELANENUDT1NCF1POLBMAPT | |
| SCHEMBL31694934 | 0.82 | ELANE (0.46) | ELANENUDT1NCF1POLBMAPT | |
| SCHEMBL18549020 | 0.82 | ELANE (0.46) | ELANENUDT1NCF1POLBMAPT | |
| SCHEMBL31694955 | 0.82 | ELANE (0.46) | ELANENUDT1NCF1POLBMAPT | |
| SCHEMBL17205186 | 0.82 | NUDT1 (0.54) | ELANENUDT1NCF1POLBMAPT | |
| SCHEMBL31694957 | 0.82 | ELANE (0.46) | ELANENUDT1NCF1POLBMAPT | |
| SCHEMBL18548997 | 0.82 | ELANE (0.46) | ELANENUDT1NCF1POLBMAPT | |
| SCHEMBL18548994 | 0.82 | ELANE (0.46) | ELANENUDT1MAPTL3MBTL1NPC1 | |
| SCHEMBL18548984 | 0.82 | ELANE (0.46) | ELANENUDT1NCF1POLBMAPT | |
| SCHEMBL31694932 | 0.82 | ELANE (0.46) | ELANENUDT1MAPTL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11173146-B2 | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-16 | — | — | US | claimed |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | UNIV CALIFORNIA (US) | 2017-03-02 | — | — | US | claimed |
| US-11173146-B2 | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-16 | — | — | US | disclosed |
| US-11173146-B2 | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-16 | — | — | US | disclosed |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | UNIV CALIFORNIA (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | UNIV CALIFORNIA (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | UNIV CALIFORNIA (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173146-B2 | Selective activators of the intermediate conductance CA2+activated K+ channel KCa3.1 and their methods of use | KCNN3, KCNN1, KCNN2 | ELANE 2595/4885NUDT1 2147/4885NCF1 1289/4885 |
| US-20170056376-A1 | SELECTIVE ACTIVATORS OF THE INTERMEDIATE CONDUCTANCE CA2+ACTIVATED K+ CHANNEL KCa3.1 AND THEIR METHODS OF USE | KCNN3, KCNN1, KCNN2 | ELANE 2595/4885NUDT1 2147/4885NCF1 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.